Skip to main content
. 2015 Feb 16;17(6):882–888. doi: 10.1093/neuonc/nov017

Fig. 1.

Fig. 1.

MRI of participant #4 from one week prior to initiating alisertib therapy (A) sagittal T1 with contrast, (B) axial T2 with contrast; (C) sagittal T1 with contrast one year on single-agent alisertib showing regression of tumor; (D) axial T2 with contrast one year on single-agent alisertib therapy showing regression of tumor that had persisted for 11.7 months.